With $588M IPO, Sana leads wave of new biotechs going public

Seattle’s Sana Biotechnology raised $588 million in its stock market debut, showcasing investors’ continued interest in the life science industry after a record-setting 2020. The company, which is still a year away from the start of its first clinical trial, far exceeded its original goal of securing $150 million. This places Sana among the largest ever valuations for a newly public biotech company.